Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice
- Eun S. Park,
- Sehee Kim,
- Shuning Huang,
- Ji Young Yoo,
- Jakob Körbelin,
- Tae Jin Lee
- University of Texas Health Science Center at Houston,
- University Medical Center Hamburg-Eppendorf
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Objective: Brain arteriovenous malformations (bAVMs) are a leading cause of hemorrhagic stroke and neurological deficits in children and young adults, however, no pharmacological intervention is available to treat these patients. Although more than 95% of bAVMs are sporadic without family history, the pathogenesis of sporadic bAVMs is largely unknown, which may account for the lack of therapeutic options. KRAS mutations are frequently observed in cancer, and a recent unprecedented finding of these mutations in human sporadic bAVMs offers a new direction in the bAVM research. Using a novel adeno-associated virus targeting brain endothelium (AAV-BR1), the current study tested if endothelial KRAS<sup>G12V</sup> mutation induces sporadic bAVMs in mice. Methods: Five-week-old mice were systemically injected with either AAV-BR1-GFP or -KRAS<sup>G12V</sup>. At 8 weeks after the AAV injection, bAVM formation and characteristics were addressed by histological and molecular analyses. The effect of MEK/ERK inhibition on KRAS<sup>G12V</sup>-induced bAVMs was determined by treatment of trametinib, a US Food and Drug Administration (FDA)-approved MEK/ERK inhibitor. Results: The viral-mediated KRAS<sup>G12V</sup> overexpression induced bAVMs, which were composed of a tangled nidus mirroring the distinctive morphology of human bAVMs. The bAVMs were accompanied by focal angiogenesis, intracerebral hemorrhages, altered vascular constituents, neuroinflammation, and impaired sensory/cognitive/motor functions. Finally, we confirmed that bAVM growth was inhibited by trametinib treatment. Interpretation: Our innovative approach using AAV-BR1 confirms that KRAS mutations promote bAVM development via the MEK/ERK pathway, and provides a novel preclinical mouse model of bAVMs which will be useful to develop a therapeutic strategy for patients with bAVM. ANN NEUROL 2021;89:926–941.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 926-941 (16 pages)Journal (Volume, Issue Number)
Annals of Neurology (Volume 89, Issue 5)Publication milestones
- Published - 05/2021
Publication status
Published - 05/2021
ISSN
0364-5134Publication IDs
- Scopus: 85102827918
- PubMed: 33675084
Publication metrics
Metrics
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Social media
52
Citation count
65
Captures
56
Funding Details
The authors thank V. S. L. Rivera for helpful discussions and manuscript revisions. This work was supported by Weatherhead Foundation and AVM Research Foundation. The authors also thank the Dipola and Theaker families for generous donations in support of this work.
FundersFunding numbers
Weatherhead Foundation
-AGA Research Foundation
-